Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

HomeAboutAboutStorage and handlingVial sizes and NDC numbersVolume illustrationsEfficacyEfficacyPivotal and extension study design and endpointsPivotal study efficacy dataExtension study efficacy dataSafety and TolerabilitySafety and
TolerabilityAdverse reactions: pivotal and extension studiesInfusion-site reactions: pivotal and extension studiesDosing and AdministrationDosing and
AdministrationFlexible infusion schedule options and infusion volume ratesInfusion duration examples (adult)Infusion duration examples (pediatric)Dosing calculatorSupportSupportMaterialsVideosPfizer IGuideTMPfizer cutaquig co-pay programIg Companion mobile app Request a representative
Full Prescribing Information & BOXED WARNINGPatient InformationIndicationsLoadingInstructions for UsePatient SiteMedical Information
Dosing and AdministrationDosing calculatorFlexible infusion
schedule options
and infusion
volume ratesInfusion duration 
examples
(adult)Infusion duration
examples
(pediatric)Dosing
calculator
Next
Start again Return to previous
Next
Start again
New Calculation
Start again
Determine Administration Regimen
Start again Return to previous
New Calculation
Return to previous
Calculate
Start again Return to previous
Try a New Calculation
Calculate
Start again
Dosing and administration calculator
{{#if this.infusionData}} Calculated weekly cutaquig dose* based on the previous monthly IVIg dose: {{infusionData.g}} g† or {{infusionData.ml}} ml† {{/if}}
Choose what you would like to calculate:
Weekly cutaquig dose calculation in grams and milliliters
Choose what to base the calculation on:
Weekly cutaquig dose calculation in grams and milliliters
Enter the previous monthly IVIg dose:
grams
Weekly cutaquig dose calculation in grams and milliliters
Calculated weekly cutaquig dose* based on the previous monthly IVIg dose: {{doseGrams}} g† or {{doseMls}} mL†
Do you want to convert this weekly dose to:

*Weekly dose based on the following formula: Weekly dose=Previous IVIg dose (in grams) × 1.30 ÷ number of weeks between IVIg doses.

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Every-other-week cutaquig dose* calculation in grams and milliliters:
{{doseGrams}} g† or {{doseMls}} mL†

*Every-other-week dose based on the following formula: Every-other-week dose=Previous weekly dose × 2.

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Weekly cutaquig dose calculation in grams and milliliters
Calculated weekly cutaquig dose* based on the previous monthly IVIg dose: {{doseGrams}} g† or {{doseMls}} mL†
Do you want to convert this weekly dose to:

*Weekly dose based on the following formula: Weekly dose=Previous IVIg dose (in grams) × 1.30 ÷ number of weeks between IVIg doses.

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Calculated weekly cutaquig dose* based on the previous monthly IVIg dose:
{{doseGrams}} g or {{doseMls}} mL
{{#if weeklyDoseFrequencyLabel}} Daily cutaquig dose* calculation in grams and milliliters: {{else}} {{weeklyDoseFrequencyText}} times a week dose* calculation in grams and milliliters: {{/if}}
{{doseGrams}} g† or {{doseMls}} mL†
{{#if weeklyDoseFrequencyLabel}}

*Daily dose based on the following formula: Daily dose=Previous weekly dose ÷ 7.

{{else}}

*{{weeklyDoseFrequencyText}} times a week dose based on the following formula: {{weeklyDoseFrequencyText}} times a week dose=Previous weekly dose ÷ {{weeklyDoseFrequency}}.

{{/if}}

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.

Weekly cutaquig dose calculation in grams and milliliters
Enter the previous weekly SCIg dose:
grams/week*

*For previous SCIg regimens that are not weekly, adjust the previous SCIg dose for a week.

Weekly cutaquig dose calculation in grams and milliliters
Calculated weekly cutaquig dose* based on the previous weekly SCIg dose: {{doseGrams}} g† or {{doseMls}} mL† Do you want to convert this weekly dose to:

*Weekly dose based on the following formula: Weekly dose=Previous SCIg dose (in grams) × 1.0.

†>Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Weekly cutaquig dose calculation in grams and milliliters
Calculated weekly cutaquig dose* based on the previous weekly SCIg dose: {{doseGrams}} g† or {{doseMls}} mL†
Do you want to convert this weekly dose to:

*Weekly dose based on the following formula: Weekly dose=Previous SCIg dose (in grams) × 1.0

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Calculated weekly cutaquig dose* based on the previous monthly SCIg dose:
{{doseGrams}} g or {{doseMls}} mL
{{#if weeklyDoseFrequencyLabel}} Daily cutaquig dose* calculation in grams and milliliters: {{else}} {{weeklyDoseFrequencyText}} times a week dose* calculation in grams and milliliters: {{/if}}
{{doseGrams}} g† or {{doseMls}} mL†
{{#if weeklyDoseFrequencyLabel}}

*Daily dose based on the following formula: Daily dose=Previous weekly dose ÷ 7.

{{else}}

*{{weeklyDoseFrequencyText}} times a week dose based on the following formula: {{weeklyDoseFrequencyText}} times a week dose=Previous weekly dose ÷ {{weeklyDoseFrequency}}.

{{/if}}

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.

Every-other-week cutaquig dose* calculation in grams and milliliters:
{{doseGrams}} g† or {{doseMls}} mL†

*Every-other-week dose based on the following formula: Every-other-week dose=Previous weekly dose × 2.

Grams and milliliters (volume) have been rounded to the nearest whole number.†

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Weekly cutaquig dose calculation in grams and milliliters
Enter patient's body weight:
lb
OR
kg
Select the patient's weekly dose
Weekly cutaquig dose calculation in grams and milliliters
Calculated weekly cutaquig dose* based on the patient’s body weight: {{doseGrams}} g† or {{doseMls}} mL†
Do you want to convert this weekly dose to:

*Weekly dose based on the following formula: Weekly dose = 102.3 kg × 0.1 g/kg.

†Grams and milliliters (volume) have been rounded to the nearest whole number.
Calculated weekly cutaquig dose* based on the previous monthly body weight :
{{doseGrams}} g or {{doseMls}} mL
Every-other-week cutaquig dose* calculation in grams and milliliters:
{{doseGrams}} g† or {{doseMls}} mL†

*Every-other-week dose based on the following formula: Every-other-week dose=Previous weekly dose × 2.

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.
Weekly cutaquig dose calculation in grams and milliliters
Calculated weekly cutaquig dose* based on the patient's body weight: {{doseGrams}} g† or {{doseMls}} mL†
Do you want to convert this weekly dose to:

*Weekly dose based on the following formula: Weekly dose = {{bodyWeight}} kg * {{weeklyDose}} g/kg.

†Grams and milliliters (volume) have been rounded to the nearest whole number.
{{#if weeklyDoseFrequencyLabel}} Daily cutaquig dose* calculation in grams and milliliters: {{else}} {{weeklyDoseFrequencyText}} times a week dose* calculation in grams and milliliters: {{/if}}
{{doseGrams}} g† or {{doseMls}} mL†
{{#if weeklyDoseFrequencyLabel}}

*Daily dose based on the following formula: Daily dose=Previous weekly dose ÷ 7.

{{else}}

*{{weeklyDoseFrequencyText}} times a week dose based on the following formula: {{weeklyDoseFrequencyText}} times a week dose=Previous weekly dose ÷ {{weeklyDoseFrequency}}.

{{/if}}

†Grams and milliliters (volume) have been rounded to the nearest whole number.

Monitor serum IgG trough levels regularly to guide subsequent dose adjustments as needed.

Number of sites, volume, and approximate infusion time {{#if this.infusionData}} {{infusionData.g}} g† or {{infusionData.ml}} ml† {{/if}}
Enter the cutaquig dose:
grams
OR
milliliters
Choose if this is the patient's:
Enter the patient’s age in years*:

*Volume per site and rate of infusion are age-dependent.

Options for the number of sites, volume, and approximate infusion time
Choose if this is the patient's:
Number of sites, volume, and approximate infusion time
Recommendation for {{#if this.oneToSixInfusions}} initial 2 infusion of a {{else}} 3rd or subsequent infusion of a {{/if}} cutaquig dose of {{doseGrams}} g or {{doseMls}} mL:
{{#each infusionTime.sites}} {{#unless @first}}

or

{{/unless}}

{{this.numInfusionSites}} infusion {{#if this.singular}}site{{else}}sites{{/if}}, {{this.dosePerSite}} mL per site with an approximate infusion time of {{this.infusionTimeMins}}*

{{/each}}
{{#if infusionTime.error}}

Sequential administration is needed for this infusion volume because it exceeds the 6 infusion sites that can be administered simultaneously per the US Prescribing Information. For guidance on sequential administration, consult with specialty pharmacy.

{{/if}}

*The time it takes to infuse depends on how many sites are used. According to the US Prescribing Information, up to 6 infusion sites may be used with infusion volumes and rates according to the table below.


{{#if this.oneToSixInfusions}}

Infusion parameters

{{else}}

Infusion volumes and rates

{{/if}}
{{{table this.tableHeaders this.tableData}}}
{{#if this.oneToSixInfusions}} {{else}}

Increase the volume by ~10 mL/site for adults and by ~5-10 mL/site for children <17 years every 2-4 weeks, as tolerated1

Increase the infusion rate by ~10 mL/hr/site for adults and by ~5-10 mL/hr/site for children <17 years every 2-4 weeks, as tolerated1

{{/if}}
Options for the number of sites, volume, and approximate infusion time
Choose the maximum infusion rate if this is the patient's seventh or subsequent infusion:
Dose adjustment for patient currently taking cutaquig

The dose may need to be individualized for each patient over time.

Measure the patient's serum IgG trough level 2 to 3 months after switching to cutaquig or after the last cutaquig dose adjustment to determine if a dose adjustment is necessary.

Choose an amount to adjust the patient's serum IgG levels*:
Is the patient on a weekly or every-other-week dosing schedule?

*Volume per site and rate of infusion are age-dependent.

Dose adjustment for patient currently taking cutaquig

Modify the {{ patientsSerumScheduleInput }} dose by the recommended incremental volume below based on the patient's body weight to adjust serum IgG levels by {{ patientsSerumAmountInput }} mg/dL

{{{table this.tableHeaders this.tableData}}}

*Derived from a linear regression model of trough level and weekly dose per kg of body weight.

Reference:
  1. Cutaquig. Prescribing information. Octapharma USA Inc.; 2021.
You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.
Demonstrated efficacy

0 SBIs occurred in any patient during the 52-week efficacy study period1

 Learn more
Proven safety profile

0 withdrawals due to adverse reactions in the phase 3 pivotal and extension studies 1

 Learn more Loading Proven safety profile

0 withdrawals due to adverse reactions in the phase 3 pivotal and extension studies 1

 Learn more

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-CQG-USA-0667
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer. PP-MCL-USA-0367

​​​​​​​
INDICATIONS AND USAGE

CUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Please see Full Prescribing Information, including BOXED WARNING and Patient Information and Instructions for Use.

Important Safety Information WARNING: THROMBOSIS
  • Thrombosis may occur with immune globulin products, including CUTAQUIG. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Full Prescribing Information, Warnings and Precautions (5.2), Patient Counseling Information (17)]
  • For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2)]
 Contraindications

CUTAQUIG is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of CUTAQUIG, such as Polysorbate 80, and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Warnings and Precautions

Severe hypersensitivity reactions may occur with CUTAQUIG, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the CUTAQUIG infusion immediately and initiate appropriate treatment. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions.

Thrombosis may occur following treatment with immune globulin products, including CUTAQUIG. For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Falsely elevated blood glucose readings may occur during and after the infusion of CUTAQUIG with some glucometer and test strip systems. When administering CUTAQUIG, measure blood glucose with a glucose-specific method.

Aseptic meningitis syndrome (AMS) can occur with CUTAQUIG. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously and may occur within 2 days following treatment. Discontinuation of immunoglobulin treatment has resulted in remission within several days without sequelae.

Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin, especially those containing sucrose. CUTAQUIG does not contain sucrose.

Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. Monitor CUTAQUIG recipients for clinical signs and symptoms of hemolysis, particularly patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after CUTAQUIG infusion.

Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. Monitor for pulmonary adverse reactions. If transfusion-related acute lung injury is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient's serum.

CUTAQUIG is made from human plasma and may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease agent, and, theoretically, the Creutzfeldt-Jakob disease agent. Adverse Reactions

The most common adverse reactions (≥5% of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, and cough.

Drug Interactions

After infusion of CUTAQUIG, the transitory rise of the various passively transferred antibodies in the patient's blood may yield false positive serological test results, with the potential for misleading interpretation.

The passive transfer of antibodies with immunoglobulin administration may interfere with the response to live virus vaccines such as measles, mumps, rubella, and varicella.

Use in Specific Populations

It is not known whether CUTAQUIG can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.

No human data are available to indicate the presence or absence of drug-associated risk to lactation and breastfeeding.

​​Overall safety and efficacy findings in pediatric age group were comparable to those seen in adults. However, infusion site reactions were more commonly observed in adults compared to the pediatric population.

Safety and effectiveness of CUTAQUIG in pediatric patients below the age of 2 have not been established.

Clinical studies of CUTAQUIG did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, to reduce the risk of hyperviscosity and precipitation of cardiac, renal, or hepatic adverse reaction, and of concomitant disease or other drug therapy. The risk information provided here is not comprehensive; see full Prescribing Information and Boxed Warning for CUTAQUIG.

You are encouraged to report adverse events related to Pfizer products by calling 1-800-438-1985 (US only). If you prefer, you may contact the US Food and Drug Administration (FDA) directly. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.

CUTAQUIG® is a registered trademark of Octapharma AG.

Please click here for Full Prescribing Information, including BOXED WARNING and Patient Information and Instructions for Use.​ Indications and UsageCUTAQUIG (Immune Globulin Subcutaneous [Human] - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.